» Articles » PMID: 23683334

Serum Cytokines Associated with Severity and Complications of Kala-azar

Overview
Date 2013 May 21
PMID 23683334
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Recent clinical data suggest that severe kala-azar (or visceral leishmaniasis) is an exaggerated innate immune response mediated by inflammatory cytokines, leading to a systemic inflammatory syndrome similar to what is observed in malaria, sepsis and other diseases. We tested this hypothesis by measuring serum cytokines in individuals with kala-azar.

Methods: We compared patients with severe kala-azar (i.e. hemorrhagic manifestations, n = 38) with patients without evidence of hemorrhage (n = 96). We conducted a detailed clinical and laboratory evaluation, measuring serum IL-1beta, IL-6, IL-8, IL-10, IL-12, interferon-gamma, and TNF-alpha, and markers of disseminated intravascular coagulation (DIC).

Results: Infants had higher levels of inflammatory cytokines, while HIV-infected patients had lower concentrations of IL-10 and interferon-gamma. Higher levels of IL-6, interferon-gamma, and IL-8 were found among deceased patients. IL-8 and interferon-gamma were independently associated with bleeding. Several cytokines were associated with different signs of severe clinical and laboratory manifestations, including DIC. IL-6 was highly positively and independently associated with IL-1beta, IL-8, IL-10, and negatively associated with TNF-alpha. IL-1beta and TNF-alpha were also highly independently associated with disease severity.

Conclusion: In its severe form, kala-azar, a neglected tropical disease, initiates a systemic inflammatory response that leads to DIC and other manifestations. Children may have higher risk of death due to the more intense cytokine release. The data supports the notion that IL-6 is the central cytokine that is associated with lethal disease, but interferon-gamma, IL1beta, IL-8, and TNF-alpha are also involved with disease severity. Inhibition of IL-6 is a potential target of adjuvant therapy for severe or pediatric forms of this disease.

Citing Articles

Cytokine profiles, blood parasite load and clinical features of visceral leishmaniasis in West Pokot County, Kenya.

van Dijk N, Carter J, Kiptanui D, Pinelli E, Schallig H Parasitology. 2024; 151(7):753-761.

PMID: 39311405 PMC: 11474019. DOI: 10.1017/S0031182024000751.


Low Plasma Lipids Are Associated with Relapsing and Lethal Visceral Leishmaniasis in HIV-Infected Patients.

Silva R, Uliana S, Yasunaka J, Veloso C, Sousa E, Ferreira M Pathogens. 2024; 13(6).

PMID: 38921748 PMC: 11206293. DOI: 10.3390/pathogens13060450.


An integrated analysis of the structural changes and gene expression of spleen in human visceral leishmaniasis with and without HIV coinfection.

Fontes J, Khouri R, Reinaldo L, Hassegawa E, Meneses Filho A, de Melo C PLoS Negl Trop Dis. 2024; 18(6):e0011877.

PMID: 38843306 PMC: 11265696. DOI: 10.1371/journal.pntd.0011877.


Visceral Leishmaniasis in a Twin Pregnancy: A Case Report and Review of the Literature.

Karampas G, Koulouraki S, Daikos G, Nanou C, Aravantinos L, Eleftheriades M J Clin Med. 2024; 13(8).

PMID: 38673673 PMC: 11051246. DOI: 10.3390/jcm13082400.


The spleen is the graveyard of CD4+ cells in patients with immunological failure of visceral leishmaniasis and AIDS.

Reinaldo L, Araujo Junior R, Diniz T, de Deus Moura R, Meneses Filho A, Furtado C Parasit Vectors. 2024; 17(1):132.

PMID: 38491526 PMC: 10941596. DOI: 10.1186/s13071-024-06151-6.


References
1.
de Jong H, van der Poll T, Wiersinga W . The systemic pro-inflammatory response in sepsis. J Innate Immun. 2010; 2(5):422-30. DOI: 10.1159/000316286. View

2.
Cai B, Deitch E, Ulloa L . Novel insights for systemic inflammation in sepsis and hemorrhage. Mediators Inflamm. 2010; 2010:642462. PMC: 2902015. DOI: 10.1155/2010/642462. View

3.
Ward N, Casserly B, Ayala A . The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients. Clin Chest Med. 2008; 29(4):617-25, viii. PMC: 2786900. DOI: 10.1016/j.ccm.2008.06.010. View

4.
Wheeler D, Zingarelli B, Wheeler W, Wong H . Novel pharmacologic approaches to the management of sepsis: targeting the host inflammatory response. Recent Pat Inflamm Allergy Drug Discov. 2009; 3(2):96-112. PMC: 2754156. DOI: 10.2174/187221309788489779. View

5.
Sprong T, Mollnes T, Neeleman C, Swinkels D, Netea M, van der Meer J . Mannose-binding lectin is a critical factor in systemic complement activation during meningococcal septic shock. Clin Infect Dis. 2009; 49(9):1380-6. DOI: 10.1086/606054. View